Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation (Q21254711)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published in 2009

Language	Label	Description	Also known as
English	Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation	scientific article published in 2009

Statements

scholarly article

0 references

systematic review

1 reference

based on heuristic

inferred from title

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation (English)

0 references

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

object named as

Yaser Adi

2

author given names

Yaser

author last names

Adi

1 reference

Dimensions Publication ID

18 August 2022

object named as

Sue Bayliss

4

author given names

Sue

author last names

Bayliss

1 reference

Dimensions Publication ID

18 August 2022

author name string

David J Moore

1

author given names

David J

author last names

Moore

1 reference

Dimensions Publication ID

18 August 2022

Martin J Connock

3

author given names

Martin J

author last names

Connock

1 reference

Dimensions Publication ID

18 August 2022

language of work or name

0 references

publication date

2009

0 references

BMC Endocrine Disorders

0 references

9

0 references

1

0 references

20

0 references

copyright license

Creative Commons Attribution 2.0 Generic

8 October 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

19 March 2017

Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

19 March 2017

Medical progress: Acromegaly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

12 September 2017

Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

12 September 2017

Systemic complications of acromegaly: epidemiology, pathogenesis, and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

12 September 2017

Epidemiology of acromegaly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

12 September 2017

An audit of outcome of treatment in acromegaly.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

27 September 2017

Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

30 May 2018

Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

30 May 2018

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Effects of a growth hormone receptor antagonist on bone markers in acromegaly

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

A nationwide survey of mortality in acromegaly

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Quality of life in treated patients with acromegaly

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Lipodystrophy in patients with acromegaly receiving pegvisomant

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Treatment with Growth Hormone Receptor Antagonist in Acromegaly: Effect on Cardiac Structure and Performance

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL)

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/19814797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization

1 reference

https://pubmed.ncbi.nlm.nih.gov/19814797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-of-illness study in acromegalic patients in Italy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19814797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of Life (QOL) in Patients with Acromegaly Is Severely Impaired: Use of a Novel Measure of QOL: Acromegaly Quality of Life Questionnaire

1 reference

https://pubmed.ncbi.nlm.nih.gov/19814797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/19814797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegvisomant interference in GH assays results in underestimation of GH levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/19814797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1186/1472-6823-9-20

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

0 references

release_vlg77ez3tnahrftvok5izsjjpi

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q21254711&oldid=2176715704"